Why a FDA nod isn't enough for Regeneron shares
June 10, 2015 at 12:49 PM EDT
Regeneron's shares sank 4 percent despite a positive Food and Drug Administration recommendation on cholesterol drug. What gives?
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|